EXEL
Exelixis IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$11.33B
P/E Ratio
15.69
EPS
$2.78
Beta
0.42
52W High
$49.62
52W Low
$33.76
50-Day MA
$43.02
200-Day MA
$41.66
Dividend Yield
—
Profit Margin
33.70%
Forward P/E
14.41
PEG Ratio
2.27
About Exelixis Inc
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Fundamentals
| Revenue (TTM) | $2.32B |
| Gross Profit (TTM) | $2.24B |
| EBITDA | $921.76M |
| Operating Margin | 39.40% |
| Return on Equity | 35.50% |
| Return on Assets | 19.30% |
| Revenue/Share (TTM) | $8.54 |
| Book Value | $8.23 |
| Price-to-Book | 5.28 |
| Price-to-Sales (TTM) | 4.88 |
| EV/Revenue | 4.533 |
| EV/EBITDA | 11.41 |
| Quarterly Earnings Growth (YoY) | 84.20% |
| Quarterly Revenue Growth (YoY) | 5.60% |
| Shares Outstanding | $254.01M |
| Float | $211.44M |
| % Insiders | 1.96% |
| % Institutions | 105.67% |
Historical Volatility
HV 10-Day
34.40%
HV 20-Day
29.90%
HV 30-Day
27.54%
HV 60-Day
30.02%
HV Rank
13.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($46.83 target)
1
Strong Buy9
Buy10
Hold1
Strong SellData last updated: 4/21/2026